Integra will pay a total of approximately $204 million in cash for the common stock and a price of $32.00 per share for outstanding shares of Series A Convertible Preferred Stock while a $48.00 price ...

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today announced that it has purchased the MEDIHONEY® brand ...

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces receipt of the CE Mark for the Company’s ...

An advanced wound care company has acquired a diabetic foot ulcer treatment firm in a $14.5 million deal. The acquisition reflects Derma Sciences’ strategy to acquire higher-margined companies with ...

Here at The Motley Fool, I've long cautioned investors to keep a close eye on inventory levels. It's a part of my standard diligence when searching for the market's best stocks. I think a quarterly ...

Derma Sciences Inc. DSCI is a medical device company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid ...

Derma Sciences and Quick-Med Technologies announce the signing of an agreement whereby Quick-Med Technologies has granted Derma Sciences an exclusive global license to intellectual property related to ...

BANGALORE – Derma Sciences Inc said foot ulcers in 85 percent of diabetic patients healed completely after being treated with its experimental drug at the end of a 24-week trial, improving its chances ...

There's no foolproof way to know the future for Derma Sciences (NAS: DSCI) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock ...

Derma Sciences, a tissue regeneration company based in Princeton, has promoted an executive to president of advanced wound care, it said Thursday.Russell Olsen is CEO and president of BioD LLC, a ...

Earlier this morning, Derma Sciences announced financial results for the 2015 fourth quarter and full year. If you have not received this news release or if you would like to be added to the company’s ...

March 29 (Reuters) - Derma Sciences Inc said it will buy privately held MedEfficiency Inc for $14.5 million to gain access to its device that will help support Derma's treatment of diabetes-induced ...